Nexus Surgical and Medicare Limited is an Indian listed entity operating as a specialized **trading house** for **medical supplies and surgical equipment**. The company functions as a lean, single-segment enterprise, positioning itself as a critical intermediary within the rapidly expanding Indian healthcare value chain. --- ### **Core Business Model and Operational Structure** The company operates exclusively within the **Trading Activity** segment, as defined by **Ind AS 108**. Its business model is built on the procurement and distribution of medical essentials, leveraging India’s position as a cost-competitive hub for pharmaceutical production and medical tourism. * **Corporate Architecture:** The company maintains a simplified corporate structure with **no subsidiaries, joint ventures, or associate companies**. * **Financial Framework:** Accounts are prepared in strict accordance with **Indian Accounting Standards (Ind AS)**. * **Capital Strategy:** The company maintains a conservative capital structure and did not raise additional finance through the issuance of new securities during the **2024-25** fiscal year. * **Compliance Status:** The company is exempt from **Cost Audit** provisions under Section 148 of the Companies Act, 2013, but adheres to rigorous **Secretarial Audits**. --- ### **Strategic Growth Drivers and Market Positioning** Nexus Surgical is strategically aligned with the "New India" healthcare narrative, which saw the domestic sector reach a valuation of **US$ 372 billion** in FY23. The company’s growth strategy is underpinned by several macroeconomic tailwinds: * **Public Health Expenditure:** The Government of India’s target to increase public health spending to **2.5% of GDP by 2025** (with a **₹ 90,959 crore** allocation in the **Union Budget 2024-25**) provides a high-ceiling environment for medical traders. * **Digital Integration:** The company is navigating a shift toward **Artificial Intelligence (AI)** and **Machine Learning (ML)** in healthcare delivery, particularly within the **Ayushman Bharat** ecosystem, which has issued over **26 crore cards**. * **Foreign Investment Inflows:** The company operates in a sector that has attracted massive cumulative FDI (April 2000 – December 2023): * **Drugs & Pharmaceuticals:** **$22.37 Billion** * **Hospitals & Diagnostic Centres:** **$9.81 Billion** * **Medical & Surgical Appliances:** **$3.26 Billion** * **Emerging Segments:** Management is monitoring the rise of **telemedicine**, **preventive healthcare**, and **decentralized diagnostic testing** as primary drivers for future equipment demand. --- ### **Financial Performance and Efficiency Metrics** The company has demonstrated a robust upward trajectory in revenue and profitability over the last three fiscal cycles. #### **Comparative Financial Summary (₹ in '00)** | Metric | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Total Revenue** | **5,72,826.06** | **3,50,107.70** | **1,56,690.34** | | **Net Profit After Tax (PAT)** | **49,738.32** | **21,330.85** | **17,070.48** | | **Net Profit Margin (%)** | **8.69%** | **6.14%** | *Not Disclosed* | #### **Key Performance Indicators (KPIs)** * **Profitability Expansion:** The **Net Profit Margin** improved significantly to **8.69%** in FY25, up from **6.14%** the previous year. * **Liquidity Strength:** The **Current Ratio** rose to **1.85 times** (from **1.41 times**), indicating a healthy cushion of current assets to meet short-term obligations. * **Asset Efficiency:** The **Debtors Turnover Ratio** saw a decline to **5.47 times** (from **8.73 times**), reflecting an increase in **trade receivables** that requires active management. * **Retention Policy:** No dividends were recommended for **FY 2024-25** or **FY 2023-24**. The company is prioritizing the **retention of earnings** to fund its future growth trajectory rather than transferring profits to General Reserves. --- ### **International Trade and Procurement Profile** While the company does not currently generate revenue in foreign denominations, it is heavily active in international procurement to source high-quality surgical equipment. | Particulars (₹ in '00) | FY 2024-25 | FY 2023-24 | | :--- | :--- | :--- | | **Earnings in Foreign Currency** | **Nil** | **Nil** | | **Expenditure in Foreign Currency** | **189,770.80** | **101,417.13** | The significant **87% increase** in foreign currency expenditure year-over-year highlights the company's expanding global supply chain and its role in bringing advanced medical technology to the Indian market. --- ### **Governance and Human Capital** The company recently reconstituted its Board of Directors following the term completion of previous members on **May 30, 2024**. * **Board Competencies:** The leadership team possesses core expertise in **Legal, Finance, IT Business Operations, Risk Management, and Governance**. * **Audit Oversight:** The Audit Committee is chaired by **Mr. Surya Kant Modi** (Independent Director). * **Audit Partners:** **M/s. Abhilasha Chaudhary & Associates** conducted the FY25 secretarial audit; **M/s. N. Bagaria & Associates** has been recommended for a 5-year term starting **FY 2025-26**. * **Workplace Culture:** The company has launched a **'Happiness at the workplace'** initiative to mitigate industry-wide burnout and improve employee retention. --- ### **Risk Management Framework** Nexus Surgical operates under a structured risk mitigation policy reviewed by the Board to address systemic and market-specific threats. #### **Financial Risk Matrix** * **Credit Risk:** Managed through **internal rating criteria** and customer credit limits to protect **trade receivables**. * **Liquidity Risk:** Monitored via **rolling cash flow forecasts** and the maintenance of **short-term fund-based lines** to ensure borrowing headroom. * **Market Risk:** The company is exposed to **foreign exchange fluctuations** due to its high import volume and **interest rate hikes** that impact borrowing costs. #### **Operational and Systemic Risks** * **Cybersecurity:** The expansion of the **Internet of Medical Things (IoMT)** and **Electronic Health Records (EHRs)** has increased vulnerability to **ransomware** and data breaches. * **Supply Chain Integrity:** The company faces risks from **counterfeit drugs**, **substandard devices**, and logistics bottlenecks. * **Macroeconomic Pressures:** High **out-of-pocket expenditure (over 60%)** in India and global inflationary pressures (such as the **Inflation Reduction Act** affecting drug pricing) create a volatile pricing environment. * **Solvency:** As of **March 2025**, auditors confirmed no material uncertainty regarding the company’s ability to meet liabilities due within **one year**, though long-term viability remains subject to market dynamics.